Frequency of hyperkalemia during optimization of guideline-directed medical therapy in ambulatory patients with HFrEF
Hyperkalemia >5.0 mmol/L is highly prevalent in patients with HFrEF receiving quadruple GDMT. Even with mild hyperkalemia, discontinuation of MRAs remains the primary strategy for managing this complication.
Authors
- Eileen Amaro-Balderas (ORCID: https://orcid.org/0000-0002-2032-1659)
- M. Revilla (ORCID: https://orcid.org/0000-0002-6202-1160)
- Eduardo Almeida‐Gutiérrez (ORCID: https://orcid.org/0000-0001-7122-7358)
- Luis Olmos-Domínguez
- José Antonio Magaña‐Serrano
- Jose A Cigarroa-Lopez
- Edith Liliana Posada‐Martínez (ORCID: https://orcid.org/0000-0002-3749-4281)
- Emerson Joachín‐Sánchez
- Adolfo Chávez‐Mendoza (ORCID: https://orcid.org/0000-0002-1031-3946)
- Genaro H. Mendoza‐Zavala
- M.J. Gómez-López
- Sonia C Juarez-Comboni
- Jonathan Samuel Chavez-Iñiguez (ORCID: https://orcid.org/0000-0003-2786-6667)
- Juan Betuel Ivey-Miranda (ORCID: https://orcid.org/0000-0001-8800-7298)
- Marissa A. Silva-García
- Moises Aceves‐Garcia
- Luis F Tejado-Gallegos
- Marco J Olalde-Roman
- Gibran Reynoso-Hernandez
- Miguel Sandoval-Jimenez
- Jairo I A Alejo-Arcos
- Kassandra Rios-Felix
Institutions
- Mexican Social Security Institute (MX)
- Hospital Civil de Guadalajara (MX)
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fcvm.2025.1562647
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca